drugset / Trial / NCT04663282
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.
Timeline
- Start
- 2021-02-04
- Primary completion
- 2022-05-28
- Completion
- 2022-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INS068 | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |